Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-39. (Canceled)

40. (New) A method for treating or preventing HCV infection in a subject, the method comprising administering to the subject an effective amount of an isolated antibody or a functional fragment thereof, the isolated antibody comprising amino acid sequences SEQ ID NO: 7 and SEQ ID NO: 8.

41. (New) The method of claim 40, wherein the isolated antibody comprises human monoclonal antibody Fab fragment e137.

42. (New) The method of claim 40 wherein the isolated antibody is a full size human monoclonal antibody.

43. (New) The method of claim 40, wherein the isolated antibody is an IgG1 molecule.

44. (New) The method of claim 40, wherein the isolated antibody or functional fragment thereof is administered in a composition for parenteral or topical use

45. (New) The method of claim 44 wherein said composition is in a gel, creme, ointment or ovule formulation.

46. (New) A method for treating or preventing HCV infection in a subject, the method comprising administering to the subject an effective amount of an isolated antibody or a functional fragment thereof, the isolated antibody comprising amino acid sequences SEQ ID NO: 9 and SEQ ID NO: 10.

47. (New) The method of claim 46, wherein the isolated antibody comprises human monoclonal antibody Fab fragment e301.

48. (New) The method of claim 46, wherein the isolated antibody is a full size human monoclonal antibody.

49. (New) The method of claim 46, wherein the isolated antibody is an IgG1 molecule.

50. (New) The method of claim 46, wherein the isolated antibody or functional fragment thereof is administered in a composition for parenteral or topical use

51. (New) The method of claim 50 wherein said composition is in a gel, creme, ointment or ovule formulation.

52. (New) A method for treating HCV infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a first isolated antibody and a second isolated antibody, the first isolated antibody comprising human monoclonal antibody Fab fragment e301 or a functional fragment thereof, and the second isolated antibody comprising human monoclonal antibody Fab fragment e137 or a functional fragment thereof.

53. (New) The method of claim 52, wherein the first isolated antibody is human monoclonal antibody Fab fragment e301 or a functional fragment thereof and the second isolated antibody is human monoclonal antibody Fab fragment e137 or a functional fragment thereof.

54. (New) The method of claim 52 wherein at least one of the first isolated antibody and second isolated antibody is a full size human monoclonal antibody.

55. (New) The method of claim 52, wherein at least one of the first isolated antibody and second isolated antibody is an IgG1 molecule.

56. (New) The method of claim 52, wherein the at least one of a first isolated antibody and a second isolated antibody, is administered in a composition for parenteral or topical use.

57. (New) The method of claim 56, wherein said composition is in a gel, creme, ointment or ovule formulation.